Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma

Journal of Immunology

Volumn 192, Issue 8, 2014, Pages 3569-3581

  Shibata, Takehiko ^a   Habiel, David M ^a   Coelho, Ana L ^a   Kunkel, Steven L ^a   Lukacs, Nicholas W ^a   Hogaboam, Cory M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ASTHMA; FEMALE; GENE EXPRESSION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; LUNG DISEASES, FUNGAL; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, VIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIRUS DISEASES;

EID: 84898632757     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302766     Document Type: Article

References (63)

1. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
2. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, C. B. Bridges, N. J. Cox, and K. Fukuda. 2004. Influenza-associated hospitalizations in the United States. JAMA 292: 1333-1340.
3. Collins, P. L., and B. S. Graham. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82: 2040-2055.
4. Silvestri, M., F. Sabatini, A. C. Defilippi, and G. A. Rossi. 2004. The wheezy infant-immunological and molecular considerations. Paediatr Respir Rev 5 Suppl A: S81-87.
5. Glezen, W. P., L. H. Taber, A. L. Frank, and J. A. Kasel. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140: 543-546.
6. Sigurs, N., P. M. Gustafsson, R. Bjarnason, F. Lundberg, S. Schmidt, F. Sigurbergsson, and B. Kjellman. 2005. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 171: 137-141.
7. Lotz, M. T., and R. S. Peebles, Jr. 2012. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr. Allergy Asthma Rep. 12: 380-387.
8. Tripp, R. A., C. Oshansky, and R. Alvarez. 2005. Cytokines and respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2: 147-149.
9. Matsuse, H., H. Hirose, T. Tsuchida, S. Fukahori, C. Fukushima, Y. Mizuta, and S. Kohno. 2007. Effects of respiratory syncytial virus infection on dendritic cells and cysteinyl leukotrienes in lung tissues of a murine model of asthma. Allergol. Int. 56: 165-169.
10. Hirose, H., H. Matsuse, S. Fukahori, T. Tsuchida, S. Tomari, T. Kawano, C. Fukushima, Y. Mizuta, and S. Kohno. 2008. Effects of repeated respiratory syncytial virus infections on pulmonary dendritic cells in a murine model of allergic asthma. Int. Arch. Allergy Immunol. 147: 197-205.
11. Tregoning, J. S., Y. Yamaguchi, J. Harker, B. Wang, and P. J. Openshaw. 2008. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J. Virol. 82: 4115-4124.
12. Lukacs, N. W., J. Smit, D. Lindell, and M. Schaller. 2007. Respiratory syncytial virus-induced pulmonary disease and exacerbation of allergic asthma. Contrib. Microbiol. 14: 68-82.
13. Palese, P. 2004. Influenza: old and new threats. Nat. Med. 10(Suppl.): S82-S87.
14. Webby, R. J., and R. G. Webster. 2003. Are we ready for pandemic influenzä Science 302: 1519-1522.
15. Rothlin, C. V., S. Ghosh, E. I. Zuniga, M. B. A. Oldstone, and G. Lemke. 2007. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131: 1124-1136.
16. Sharif, M. N., D. Sosic, C. V. Rothlin, E. Kelly, G. Lemke, E. N. Olson, and L. B. Ivashkiv. 2006. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203: 1891-1901.
17. Scott, R. S., E. J. McMahon, S. M. Pop, E. A. Reap, R. Caricchio, P. L. Cohen, H. S. Earp, and G. K. Matsushima. 2001. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411: 207-211.
18. Lee, W. P., Y. Liao, D. Robinson, H. J. Kung, E. T. Liu, and M. C. Hung. 1999. Axl-gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity. Mol. Cell. Biol. 19: 8075-8082.
19. Lemke, G., and C. V. Rothlin. 2008. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 8: 327-336.
20. Chen, J., K. Carey, and P. J. Godowski. 1997. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 14: 2033-2039.
21. Fisher, P. W., M. Brigham-Burke, S. J.Wu, J. Luo, J. Carton, K. Staquet,W. Gao, S. Jackson, D. Bethea, C. Chen, et al. 2005. A novel site contributing to growtharrest-specific gene 6 binding to its receptors as revealed by a human monoclonal antibody. Biochem. J. 387: 727-735.
22. Nagata, K., K. Ohashi, T. Nakano, H. Arita, C. Zong, H. Hanafusa, and K. Mizuno. 1996. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J. Biol. Chem. 271: 30022-30027.
23. Ekman, C., A. Jönsen, G. Sturfelt, A. A. Bengtsson, and B. Dahlbäck. 2011. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 50: 1064-1069.
24. Jiang, L., C. Y. Liu, Q. F. Yang, P. Wang, and W. Zhang. 2009. Plasma level of growth arrest-specific 6 (GAS6) protein and genetic variations in the GAS6 gene in patients with acute coronary syndrome. Am. J. Clin. Pathol. 131: 738-743.
25. Mc Cormack, O., W. Y. Chung, P. Fitzpatrick, F. Cooke, B. Flynn, M. Harrison, E. Fox, E. Gallagher, A. M. Goldrick, P. A. Dervan, et al. 2008. Growth arrestspecific gene 6 expression in human breast cancer. Br. J. Cancer 98: 1141-1146.
26. Borgel, D., S. Clauser, C. Bornstain, I. Bièche, A. Bissery, V. Remones, J. Y. Fagon, M. Aiach, and J. L. Diehl. 2006. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit. Care Med. 34: 219-222.
27. Fiebeler, A., J.-K. Park, D. N. Muller, C. Lindschau, M. Mengel, S. Merkel, B. Banas, F. C. Luft, and H. Haller. 2004. Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am. J. Kidney Dis. 43: 286-295.
28. Angelillo-Scherrer, A., P. de Frutos, C. Aparicio, E. Melis, P. Savi, F. Lupu, J. Arnout, M. Dewerchin, M. Hoylaerts, J. Herbert, et al. 2001. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. 7: 215-221.
29. Paccez, J. D., M. Vogelsang, M. I. Parker, and L. F. Zerbini. 2014. The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Int. J. Cancer 134: 1024-1033.
30. Paccez, J. D., G. J. Vasques, R. G. Correa, J. F. Vasconcellos, K. Duncan, X. Gu, M. Bhasin, T. A. Libermann, and L. F. Zerbini. 2013. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 32: 689-698.
31. Hong, J., D. Peng, Z. Chen, V. Sehdev, and A. Belkhiri. 2013. ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res. 73: 331-340.
32. Bosurgi, L., J. H. Bernink, V. Delgado Cuevas, N. Gagliani, L. Joannas, E. T. Schmid, C. J. Booth, S. Ghosh, and C. V. Rothlin. 2013. Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc. Natl. Acad. Sci. USA 110: 13091-13096.
33. Zhang, Z., J. C. Lee, L. Lin, V. Olivas, V. Au, T. LaFramboise, M. Abdel-Rahman, X. Wang, A. D. Levine, J. K. Rho, et al. 2012. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44: 852-860.
34. Sullivan, B. M., M. J. Welch, G. Lemke, and M. B. Oldstone. 2013. Is the TAM receptor Axl a receptor for lymphocytic choriomeningitis virus? J. Virol. 87: 4071-4074.
35. Jemielity, S., J. J. Wang, Y. K. Chan, A. A. Ahmed, W. Li, S. Monahan, X. Bu, M. Farzan, G. J. Freeman, D. T. Umetsu, et al. 2013. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog. 9: e1003232.
36. Bhattacharyya, S., A. Zagórska, E. D. Lew, B. Shrestha, C. V. Rothlin, J. Naughton, M. S. Diamond, G. Lemke, and J. A. Young. 2013. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 14: 136-147.
37. Meertens, L., X. Carnec, M. P. Lecoin, R. Ramdasi, F. Guivel-Benhassine, E. Lew, G. Lemke, O. Schwartz, and A. Amara. 2012. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12: 544-557.
38. Morizono, K., Y. Xie, T. Olafsen, B. Lee, A. Dasgupta, A. M. Wu, and I. S. Chen. 2011. The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9: 286-298.
39. Mercer, J. 2011. Viral apoptotic mimicry party: P.S. Bring your own Gas6. Cell Host Microbe 9: 255-257.
40. Shimojima, M., A. Takada, H. Ebihara, G. Neumann, K. Fujioka, T. Irimura, S. Jones, H. Feldmann, and Y. Kawaoka. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80: 10109-10116.
41. Lukacs, N.W., M. L. Moore, B. D. Rudd, A. A. Berlin, R. D. Collins, S. J. Olson, S. B. Ho, and R. S. Peebles, Jr. 2006. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am. J. Pathol. 169: 977-986.
42. Ye, X., Y. Li, S. Stawicki, S. Couto, J. Eastham-Anderson, D. Kallop, R. Weimer, Y. Wu, and L. Pei. 2010. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29: 5254-5264.
43. Hogaboam, C. M., K. Blease, B. Mehrad, M. L. Steinhauser, T. J. Standiford, S. L. Kunkel, and N. W. Lukacs. 2000. Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis during allergic airway disease induced by Aspergillus fumigatus. Am. J. Pathol. 156: 723-732.
44. Hussell, T., A. Godlee, S. Salek-Ardakani, and R. J. Snelgrove. 2012. Respiratory viral infections: knowledge based therapeutics. Curr. Opin. Immunol. 24: 438-443.
45. Ye, F., L. Han, Q. Lu, W. Dong, Z. Chen, H. Shao, H. J. Kaplan, Q. Li, and Q. Lu. 2011. Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice. J. Immunol. 187: 4178-4186.
46. Maddox, D. M., W. L. Hicks, D. Vollrath, M. M. LaVail, J. K. Naggert, and P. M. Nishina. 2011. An ENU-induced mutation in the Mertk gene (Mertknmf12) leads to a slow form of retinal degeneration. Invest. Ophthalmol. Vis. Sci. 52: 4703-4709.
47. Wang, Y., G. Moncayo, P. Morin, Jr., G. Xue, M. Grzmil, M. M. Lino, V. Clément-Schatlo, S. Frank, A. Merlo, and B. A. Hemmings. 2013. Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32: 872-882.
48. Habibi, M. S., and P. J. Openshaw. 2012. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr. Opin. Infect. Dis. 25: 687-694.
49. Carrera Silva, E. A., P. Y. Chan, L. Joannas, A. E. Errasti, N. Gagliani, L. Bosurgi, M. Jabbour, A. Perry, F. Smith-Chakmakova, D. Mucida, et al. 2013. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity 39: 160-170.
50. Tate, M. D., Y. M. Deng, J. E. Jones, G. P. Anderson, A. G. Brooks, and P. C. Reading. 2009. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J. Immunol. 183: 7441-7450.
51. Sun, J., R. Madan, C. L. Karp, and T. J. Braciale. 2009. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat. Med. 15: 277-284.
52. Tjwa, M., L. Bellido-Martin, Y. Lin, E. Lutgens, S. Plaisance, F. Bono, N. Delesque-Touchard, C. Hervé, R. Moura, A. D. Billiau, et al. 2008. Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood 111: 4096-4105.
53. Gjerdrum, C., C. Tiron, T. Høiby, I. Stefansson, H. Haugen, T. Sandal, K. Collett, S. Li, E. McCormack, B. T. Gjertsen, et al. 2010. Axl is an essential epithelial-tomesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. USA 107: 1124-1129.
54. Korns, D., S. C. Frasch, R. Fernandez-Boyanapalli, P. M. Henson, and D. L. Bratton. 2011. Modulation of macrophage efferocytosis in inflammation. Front. Immunol. 2: 57.
55. Lucas, M., L. M. Stuart, J. Savill, and A. Lacy-Hulbert. 2003. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J. Immunol. 171: 2610-2615.
56. Stuart, L. M., M. Lucas, C. Simpson, J. Lamb, J. Savill, and A. Lacy-Hulbert. 2002. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J. Immunol. 168: 1627-1635.
57. Byrne, A., and D. J. Reen. 2002. Lipopolysaccharide induces rapid production of IL-10 by monocytes in the presence of apoptotic neutrophils. J. Immunol. 168: 1968-1977.
58. Fadok, V. A., D. L. Bratton, A. Konowal, P. W. Freed, J. Y. Westcott, and P. M. Henson. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-b, PGE2, and PAF. J. Clin. Invest. 101: 890-898.
59. Finkelman, F. D., S. P. Hogan, G. K. K. Hershey, M. E. Rothenberg, and M. Wills-Karp. 2010. Importance of cytokines in murine allergic airway disease and human asthma. J. Immunol. 184: 1663-1674.
60. Barlow, J. L., A. Bellosi, C. S. Hardman, L. F. Drynan, S. H. Wong, J. P. Cruickshank, and A. N. J. McKenzie. 2011. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. Journal of Allergy and Clinical Immunology.
61. Seki, Y., H. Inoue, N. Nagata, K. Hayashi, S. Fukuyama, K.Matsumoto, O. Komine, S. Hamano, K. Himeno, K. Inagaki-Ohara, et al. 2003. SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses. Nat. Med. 9: 1047-1054.
62. Aoki, T., Y. Matsumoto, K. Hirata, K. Ochiai, M. Okada, K. Ichikawa, M. Shibasaki, T. Arinami, R. Sumazaki, and E. Noguchi. 2009. Expression profiling of genes related to asthma exacerbations. Clin. Exp. Allergy 39: 213-221.
63. Zhao, J., M. Takamura, A. Yamaoka, Y. Odajima, and Y. Iikura. 2002. Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood. Pediatr. Allergy Immunol. 13: 47-50.